Phase II results cognitive impairment schizophrenia
Presented at ECNP Congress, Phase II trial results demonstrated improvement in cognition with BI 425809 in schizophrenia patients
Search
Boehringer Ingelheim announces appointments
Boehringer Ingelheim announces appointments
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Boehringer acquires T3 Pharma
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Interview with Michael Schmelmer
"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
Breakthrough Phase 2 survodutide data liver fibrosis MASH
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
BI Focuses COVID-19 Clinical Research on Alteplase
BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems
Partnership to Develop Urea Cycle Disorders Therapy
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
FIBRONEER™ Phase III program initiated
FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
Heart murmur in dogs: symptoms and how to treat it
Monitoring your dog’s heart can save its life
Chronic kidney disease is a silent killer
Living with chronic kidney disease can have drastic impacts on a patient and their family’s life. A patient and her caregiver share their story on managing it.
Implementing the generalized pustular psoriasis (GPP) Charter
Read more about the projects are implementing the generalized pustular psoriasis (GPP) Charter
weBuy
Supplier Information: WeBuy is a key initiative in order to have an integrated solution for the Source to Procure Process around the globe.
Keep water clean
Human beings can’t survive without water. Further, the safe production of medicines depends on clean drinking water.
Digital innovation: Our digital pipeline is only growing
BRASS, a software advancing patient safety and developed fully in-house, has been sold. This is proof: our digital innovations are in demand.
EFPIA disclosure
Disclosure of Boehringer Ingelheim affiliates in countries with EFPIA member associations.
Spotlight on GPP
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
InSensitive Content: the impact on dermatologists
Learn about the importance of the dermatology community sharing content related to generalized pustular psoriasis on social media.
InSensitive Content: impact on the GPP patient community
Understand why the patient community should be able to post and consume visual content related to generalized pustular psoriasis.